pharma · Dry Eye · Conjunctivitis, Allergic · ALDX
Aldeyra Therapeutics
Aldeyra Therapeutics is a pharma organization headquartered in Lexington, USA. It trades on NYSE under ticker ALDX. Primary therapeutic focus areas include Dry Eye, Conjunctivitis, Allergic, Dry Eye Syndromes, Non-infect
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US HQ
2004 Founded
14 Employees
Public company Type
ALDX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
- Founded
- 2004
- Employees
- 14
- Programs
- 26
- Drugs
- 12
- Patents
- 38
ADX-629
Phase 2 · small molecule · Nephrotic Syndrome
ADX-629 for Nephrotic Syndrome is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ADX-629-MCD-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aldeyra Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Nephrotic Syndrome
- Status
- terminated
- Trials
- 1